{
    "nctId": "NCT01672021",
    "briefTitle": "Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients",
    "officialTitle": "Initial Assessment of 18FDG-PET/MRI in Determining the Extent of Systemic Disease in Breast Cancer Patients.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Number of metastatic lesions seen on PET/MRI as compared with PET/CT",
    "eligibilityCriteria": "Inclusion Criteria:\n\nAny patient with a history or breast cancer undergoing PET/CT either for initial staging or for disease surveillance\n\n-\n\nExclusion Criteria:\n\n* Pregnant patients and patients with known contraindications for whole body MR imaging (e.g., pacemakers, recent surgery, brain vascular clips, etc.) will be excluded from the study. Patients will be screened with a questionnaire to be sure they have no medical devices that could make the procedure unsafe. Patients with glomerular filtration rate (GFR) \\< 15 ml/min/1.73m2 or who are on dialysis will be excluded from the study.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}